

Respiratory Inhalers - Market Insights, Competitive Landscape and Market Forecast-2027

Medical Market (7-10 Business Days) | 2022-07-01 | 100 pages | DelveInsight

AVAILABLE LICENSES:

- Single User Price \$2750.00
- Site License Price \$5500.00
- Enterprise Price \$8250.00

Report description:

Respiratory Inhalers Market By Product Type (Dry Powder Inhaler, Metered Dose Inhaler, Soft Mist Inhalers, Nebulizers [Ultrasonic Nebulizers, Mesh Nebulizers, And Compressor Nebulizers]), By Type (Conventional Inhaler Devices And Smart Inhaler Devices), By Patient Type (Adult And Pediatrics), By Indication (Asthma, COPD, And Others), by geography, is expected to grow at a significant CAGR forecast till 2027 due to the escalating prevalence of pulmonary disorders across the globe and growing approvals of various respiratory inhalers.

The global respiratory inhalers market is expected to reach USD 50.40 billion by 2027 growing at a CAGR of 5.38% during the forecast period from 2022 to 2027. The respiratory inhalers market is gaining momentum owing to the rapidly rising cases of respiratory disorders such as asthma, chronic obstructive pulmonary disorders (COPD), and others. Moreover, decreasing air quality in industrialized areas due to increasing air pollution is also a key factor propelling the respiratory inhalers market. In addition, the growing adoption of digital technology by key pharmaceutical players to provide better respiratory disorder management solutions along with the increase in product approvals will contribute to the respiratory inhalers market growth.

Respiratory Inhalers Market Dynamics:

The increase in demand for respiratory inhalers is primarily attributed to the rising prevalence of pulmonary disorders such as cystic fibrosis, COPD, and others across the globe. For instance, asthma is a major chronic respiratory disease affecting both adults and children. According to the data released by the World Health Organization (WHO) in the year 2021, approximately 262

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

million people worldwide were affected by asthma in the year 2019. The report also stated that most of the asthma-related cases occurred in low- and lower-middle-income countries. Moreover, as per the Global Asthma Report 2018, in India, about 6% of children and 2% of adults have asthma in the same year. Therefore, the growing cases of asthma will lead to increase demand for various respiratory inhalers as these inhalers allow the medication to directly enter into the lungs when breathed through the mouth thereby relaxing the muscles and opening the airway, allowing more air to move in and out of the lungs for easy and comfortable breathing.

Furthermore, deteriorating air quality and an increase in air pollutants to several folds due to rapid urbanization have led to a steady increase in respiratory illness which in turn will lead to the market growth for respiratory inhalers. According to WHO 2021 report, an estimated 91% of the world population in the year 2016 lived in places where air quality exceeded WHO guideline limits. Rising air pollution is found to increase the risk of several respiratory-associated discomforts.

Additionally, rising product approvals of various respiratory inhalers are also expected to spur the market for respiratory inhalers. For instance, in May 2020, Iconovo received CE mark approval for its capsule-based dry powder inhaler ICOcap for use in clinical trials.

Henceforth, the above-mentioned factors will contribute to the global Respiratory Inhalers market growth during the forecasted period.

However, certain factors such as the lack of a single, effective device for every respiratory disorder and availability of alternative therapies such as oral medications, subcutaneous injections are expected to pose a challenge to the respiratory inhalers market growth.

Also, the unprecedented outbreak of the COVID-19 pandemic is expected to have a limited effect on the respiratory inhalers market. This is because COVID infection severely affects the lungs and it is estimated that people may develop respiratory illness as an after effect which will surge the demand for respiratory inhalers among the COVID recovering patients. Also, various clinical trials are ongoing at present to study the efficacy of asthma inhalers on COVID-19 patients. Furthermore, the launch of vaccines and their administration across the globe will normalize the market situation in the post-pandemic situation.

Respiratory Inhalers Market Segment Analysis:

Respiratory Inhalers Market By Product Type (Dry Powder Inhaler, Metred Dose Inhaler, Soft Mist Inhaler, Nebulizers [Ultrasonic Nebulizers, Mesh Nebulizers, and Compressor Nebulizers]), By Type (Conventional Inhaler Devices and Smart Inhaler Devices), By Patient Type (Adult and Paediatrics), By Indication (Asthma, COPD, and Others), and By Geography (North America, Europe, Asia-Pacific, and Rest of the World).

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

In the respiratory inhalers type segment, the smart inhaler devices segment is expected to hold a significant market share during the forecasted period. This is owing to the growing pharmaceutical companies collaborating with digital health companies for developing smart inhaler devices. For instance, in May 2020, Propeller Health, one of the leading digital health companies dedicated to the management of asthma and COPD received FDA clearance to bring its connected platform to AstraZeneca's Symbicort to help digitize the treatment of asthma and chronic obstructive pulmonary disease (COPD).

Also, the advantages associated with smart inhalers such as accuracy in drug dosage, assisting discussions between clinicians and patients, among others are projected to increase the demand for smart inhaler-type devices.

Moreover, the rising approval of connected devices is also a factor contributing to the segmental growth of the respiratory inhalers market. For instance, on December 07, 2020, AireHealth, an innovative digital health company received 510(k) clearance for its connected nebulizer. The device is a portable, electronic vibrating mesh nebulizer designed to nebulize liquid medications for inhalation by a patient in and out of the home and will be marketed under the brand name VitalMed.

Hence, all the aforementioned factors will lead to the segmental growth of the respiratory inhalers market in the coming years.

North America is expected to dominate the Overall Respiratory Inhalers Market:

Among all the regions, North America is expected to occupy a major share in the overall respiratory inhalers market during the forthcoming years. This domination is owing to the increasing prevalence of COPD in the region. Additionally, increase in adoption of technologically advanced respiratory inhalers, growing product launches associated with inhalers in the region, presence of well-established healthcare facilities, and rising government initiatives to raise awareness regarding respiratory disorders and their proper management in the region, among others.

Further, in the United States, rising smoking and related disorders are also expected to fuel the market for respiratory inhalers. For instance, as per the Centres for Disease Control and Prevention (CDC) 2019 report, nearly 14 of every 100 US adults aged 18 years or older (14.0%) smoked cigarettes. This means an estimated 34.1 million adults in the United States currently smoke cigarettes and more than 16 million Americans live with a smoking-related disease. Smoking is a major risk factor associated with the development of COPD disorder among the population. Also, based on the American Lung Association data, in 2018, 16.4 million people, or 6.6% of adults, reported a diagnosis of any type of COPD (chronic bronchitis, emphysema, or COPD). The COPD rates among adults ranged from 4.0% in Hawaii to 15.3% in West Virginia. In addition, according to the Canadian Tobacco and Nicotine Survey (CTNS) 2019 statistics, the prevalence of cigarette smoking in 2019 was 12% (3.7 million) and there was no difference in the prevalence of smoking between men (13% or 1.9 million) and women (11% or 1.7 million). Thus, increasing the risk among the population of developing COPD and other respiratory disorders.

Also, recent product approvals in the region will further augment the market for smart inhalers in the region. For instance in July 2020, Teva Respiratory, LLC., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. launched ProAir Digihaler (albuterol sulfate 117 mcg) Inhalation Powder for Patients with Asthma and COPD.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Furthermore, Europe and Asia-Pacific regions have the future potential growth for the global respiratory inhalers market. The presence of key players such as GlaxoSmithKline, AstraZeneca, and Teva pharmaceuticals, among others is likely to drive the market. In addition, products launch by the companies present in the region is also expected to bolster the market for respiratory devices. For instance, in October 2020, Zydus Cadila launched India's first pressurized Metered Dose inhalers for patients suffering from Chronic Obstructive Pulmonary Disease. Moreover, rising geriatric population, increase in air pollution level in the region, growing cases of asthma and other pulmonary diseases, an increase in disposable income, rapid urbanization, improving healthcare facilities, and integration of IoT and digitalization in the healthcare system in the region are the factors that are likely to drive the market for respiratory inhalers.

Respiratory Inhalers Market Key Players:

Some of the key market players operating in the Respiratory Inhalers market include Novartis AG, AstraZeneca, GlaxoSmithKline plc, CHIESI Farmaceutici S.p.A., Lupin, Zydus Cadila, Teva Pharmaceutical Industries Ltd., OMRON, Koninklijke Philips N.V., PARI GmbH, Boehringer Ingelheim International GmbH., Glenmark Pharmaceuticals Limited, Lepu Medical Technology(Beijing)Co.,Ltd., Rossmax International Ltd, Promed Technology Co., Limited, HELTMAN Medikal A.S., Pneuma Respiratory., Cipla Inc., Microlife Corporation., Honsun, and others.

Recent Developmental Activities in the Respiratory Inhalers Market:

? In September 2020, GlaxoSmithKline plc and Innoviva, Inc. received FDA approval for Trelegy Ellipta as the first once-daily single inhaler triple therapy for the treatment of both asthma and COPD in the US.

? In July 2020, Novartis received the European Commission (EC) approval for Enerzair Breezhaler, including the first digital companion (sensor and app) that can be prescribed alongside treatment for uncontrolled asthma in the EU.

? In January 2020, Aptar Pharma partnered with Lupin to launch India's first connected smart device for respiratory disease, ADHERO.

Key Takeaways from the Respiratory Inhalers Market Report Study

? Market size analysis for current market size (2021), and market forecast for 5 years (2022-2027)

? The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the Respiratory Inhalers market.

? Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years

? Key companies dominating the Global Respiratory Inhalers Market.

? Various opportunities available for the other competitor in the Respiratory Inhalers Market space.

? What are the top-performing segments in 2021? How these segments will perform in 2027.

? Which are the top-performing regions and countries in the current market scenario?

? Which are the regions and countries where companies should have concentrated on opportunities for Respiratory Inhalers market growth in the coming future?

Target Audience who can be benefited from the Respiratory Inhalers Market Report Study

? Respiratory Inhalers providers

? Research organizations and consulting companies

? Respiratory Inhalers-related organization, association, forum, and other alliances

? Government and corporate offices

? Start-up companies, venture capitalists, and private equity firms

? Distributors and Traders in Respiratory Inhalers

? Various End-users who want to know more about the Respiratory Inhalers Market and the latest technological developments in the Respiratory Inhalers market.

Frequently Asked Questions for the Respiratory Inhalers Market:

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

1. What are Respiratory Inhalers?

Respiratory Inhalers are portable devices used to deliver medications for chronic obstructive pulmonary disease (COPD) and asthma into the airways. They are used to prevent and treat exacerbations of these chronic conditions. They offer the advantage of avoiding the systemic effects of drugs while ensuring that drugs are delivered right where they are needed.

2. What is the market for Global Respiratory Inhalers?

The global respiratory inhalers market is expected to reach USD 50.40 billion by 2027 growing at a CAGR of 5.38% during the forecast period from 2022 to 2027.

3. What are the drivers for the Global Respiratory Inhalers?

The major factors driving the demand for Respiratory Inhalers are the rising cases of pulmonary disorders such as asthma, COPD, among others. Moreover, growing air pollution levels, increasing burden of the old age population are also some of the factors. Further, the integration of digitalization in the existing respiratory inhalers is also a factor leading to market growth.

4. What are the key players operating in Global Respiratory Inhalers?

Some of the key market players operating in the Respiratory Inhalers market include Novartis AG, AstraZeneca, GlaxoSmithKline plc, CHIESI Farmaceutici S.p.A., Lupin, Zydus Cadila, Teva Pharmaceutical Industries Ltd., OMRON, Koninklijke Philips N.V., PARI GmbH, Boehringer Ingelheim International GmbH., Glenmark Pharmaceuticals Limited, Lepu Medical Technology(Beijing)Co.,Ltd., Rossmax International Ltd, Promed Technology Co., Limited, HELTMAN Medikal A.S., Pneuma Respiratory., Cipla Inc., Microlife Corporation., Honsun, and others.

5. Which region has the highest share in the Respiratory Inhalers market?

Among all the regions, North America is expected to occupy a major share in the overall respiratory inhalers market during the forthcoming years. This domination is owing to the increasing prevalence of COPD in the region. Additionally, increase in adoption of technologically advanced respiratory inhalers, growing product launches associated with inhalers in the region, presence of well-established healthcare facilities, and rising government initiatives to raise awareness regarding respiratory disorders and their proper management in the region, among others.

Table of Contents:

- 1.Respiratory Inhalers Market Report Introduction
- 2.Respiratory Inhalers Market Executive summary
 - 2.1 Scope of the Study
 - 2.2 Market at Glance
 - 2.3 Competitive Assessment

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 2.4 Financial Benchmarking
- 3. Regulatory and Patent Analysis
 - 3.1 The United States
 - 3.2 Europe
 - 3.3 Japan
 - 3.4 China
- 4. Respiratory Inhalers Market Key factors analysis
 - 4.1 Respiratory Inhalers Market Drivers
 - 4.1.1 Growing prevalence of Pulmonary Disorders
 - 4.1.2 Increasing product launches across the globe
 - 4.1.3 Growing adoption of digital technology by key pharmaceutical players
 - 4.1.4 The rising level of air pollution worldwide
 - 4.2 Respiratory Inhalers Market Restraints and Challenges
 - 4.2.1 Availability of alternative therapies
 - 4.2.2 High Prices of Smart Inhalers along with safety concerns
 - 4.3 Respiratory Inhalers Market Opportunities
 - 4.3.1 Growth opportunities in low-income regions
 - 4.3.2 Growth opportunities due to business strategic activities by key players
- 5. Respiratory Inhalers Porter's Five Forces Analysis
 - 5.1 Bargaining Power of Suppliers
 - 5.2 Bargaining Power of Consumers
 - 5.3 Threat of New Entrants
 - 5.4 Threat of Substitutes
 - 5.5 Competitive Rivalry
- 6. COVID-19 Impact Analysis on Respiratory Inhalers Market
- 7. Respiratory Inhalers Market layout
 - 7.1 By Product Type
 - 7.1.1 Dry-Powder Inhalers
 - 7.1.2 Metred Dosed Inhalers
 - 7.1.3 Soft Mist Inhalers
 - 7.1.4 Nebulizers
 - 7.1.4.1 Mesh Nebulizers
 - 7.1.4.2 Compressor Nebulizers
 - 7.1.4.3 Ultrasonic Nebulizers
 - 7.2 By Type
 - 7.2.1 Conventional Inhaler Devices
 - 7.2.2 Smart Inhaler Devices
 - 7.3 By Patient Type
 - 7.3.1 Adult
 - 7.3.2 Pediatrics
 - 7.4 By Indication
 - 7.4.1 Asthma
 - 7.4.2 COPD
 - 7.4.3 Others
 - 7.5 By Geography
 - 7.5.1 North America

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 7.5.1.1 North America Respiratory Inhalers Market, by Product Type
- 7.5.1.2 North America Respiratory Inhalers Market, by Type
- 7.5.1.3 North America Respiratory Inhalers Market, by Patient Type
- 7.5.1.4 North America Respiratory Inhalers Market, by Indication
- 7.5.1.5 North America Respiratory Inhalers Market, by Country
 - 7.5.1.5.1 United States
 - 7.5.1.5.2 Canada
 - 7.5.1.5.3 Mexico
- 7.5.2 Europe
 - 7.5.2.1 Europe Respiratory Inhalers Market, by Product Type
 - 7.5.2.2 Europe Respiratory Inhalers Market, by Type
 - 7.5.2.3 Europe Respiratory Inhalers Market, by Patient Type
 - 7.5.2.4 Europe Respiratory Inhalers Market, by Indication
 - 7.5.2.5 Europe Respiratory Inhalers Market, by Country
 - 7.5.2.5.1 France
 - 7.5.2.5.2 Germany
 - 7.5.2.5.3 United Kingdom
 - 7.5.2.5.4 Italy
 - 7.5.2.5.5 Spain
 - 7.5.2.5.6 Russia
 - 7.5.2.5.7 Rest of Europe
- 7.5.3 Asia-Pacific
 - 7.5.3.1 Asia-Pacific Respiratory Inhalers Market, by Product Type
 - 7.5.3.2 Asia-Pacific Respiratory Inhalers Market, by Type
 - 7.5.3.3 Asia-Pacific Respiratory Inhalers Market, by Patient Type
 - 7.5.3.4 Asia-Pacific Respiratory Inhalers Market, by Indication
 - 7.5.3.5 Asia-Pacific Respiratory Inhalers Market, by Country
 - 7.5.3.5.1 China
 - 7.5.3.5.2 Japan
 - 7.5.3.5.3 India
 - 7.5.3.5.4 Australia
 - 7.5.3.5.5 South Korea
 - 7.5.3.5.6 Rest of Asia Pacific
- 7.5.4 Rest of the World (RoW)
 - 7.5.4.1 RoW Respiratory Inhalers Market, by Product Type
 - 7.5.4.2 RoW Respiratory Inhalers Market, by Type
 - 7.5.4.3 RoW Respiratory Inhalers Market, by Patient Type
 - 7.5.4.4 RoW Respiratory Inhalers Market, by Indication
 - 7.5.4.5 RoW Respiratory Inhalers Market, by Region
 - 7.5.4.5.1 Middle East
 - 7.5.4.5.2 Africa
 - 7.5.4.5.3 South America
- 8. Respiratory Inhalers Global Company Share Analysis - Key 3-5 Companies
- 9. Respiratory Inhalers Company and Product Profiles
 - 9.1 Novartis AG
 - 9.1.1. Company Overview

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.1.2. Company Snapshot
- 9.1.3. Financial Overview
- 9.1.4 Product Listing
- 9.1.5. Entropy
- 9.2 AstraZeneca
 - 9.2.1. Company Overview
 - 9.2.2. Company Snapshot
 - 9.2.3. Financial Overview
 - 9.2.4 Product Listing
 - 9.2.5. Entropy
- 9.3 GlaxoSmithKline plc
 - 9.3.1. Company Overview
 - 9.3.2. Company Snapshot
 - 9.3.3. Financial Overview
 - 9.3.4 Product Listing
 - 9.3.5. Entropy
- 9.4 CHIESI Farmaceutici S.p.A.
 - 9.4.1. Company Overview
 - 9.4.2. Company Snapshot
 - 9.4.3. Financial Overview
 - 9.4.4 Product Listing
 - 9.4.5. Entropy
- 9.5 Lupin
 - 9.5.1. Company Overview
 - 9.5.2. Company Snapshot
 - 9.5.3. Financial Overview
 - 9.5.4 Product Listing
 - 9.5.5. Entropy
- 9.6 Zydus Cadila
 - 9.6.1. Company Overview
 - 9.6.2. Company Snapshot
 - 9.6.3. Financial Overview
 - 9.6.4 Product Listing
 - 9.6.5. Entropy
- 9.7 Teva Pharmaceutical Industries Ltd.
 - 9.7.1. Company Overview
 - 9.7.2. Company Snapshot
 - 9.7.3. Financial Overview
 - 9.7.4 Product Listing
 - 9.7.5. Entropy
- 9.8 OMRON
 - 9.8.1. Company Overview
 - 9.8.2. Company Snapshot
 - 9.8.3. Financial Overview
 - 9.8.4 Product Listing
 - 9.8.5. Entropy
- 9.9 Koninklijke Philips N.V.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.9.1. Company Overview
- 9.9.2. Company Snapshot
- 9.9.3. Financial Overview
- 9.9.4 Product Listing
- 9.9.5. Entropy
- 9.10 PARI GmbH
- 9.10.1. Company Overview
- 9.10.2. Company Snapshot
- 9.10.3. Financial Overview
- 9.10.4 Product Listing
- 9.10.5. Entropy
- 9.11 Boehringer Ingelheim International GmbH.
- 9.11.1. Company Overview
- 9.11.2. Company Snapshot
- 9.11.3. Financial Overview
- 9.11.4 Product Listing
- 9.11.5. Entropy
- 9.12 Glenmark Pharmaceuticals Limited
- 9.12.1. Company Overview
- 9.12.2. Company Snapshot
- 9.12.3. Financial Overview
- 9.12.4 Product Listing
- 9.12.5. Entropy
- 9.13 Lepu Medical Technology(Beijing)Co.,Ltd.
- 9.13.1. Company Overview
- 9.13.2. Company Snapshot
- 9.13.3. Financial Overview
- 9.13.4 Product Listing
- 9.13.5. Entropy
- 9.14 Rossmax International Ltd
- 9.14.1. Company Overview
- 9.14.2. Company Snapshot
- 9.14.3. Financial Overview
- 9.14.4 Product Listing
- 9.14.5. Entropy
- 9.15 Promed Technology Co., Limited
- 9.15.1. Company Overview
- 9.15.2. Company Snapshot
- 9.15.3. Financial Overview
- 9.15.4 Product Listing
- 9.15.5. Entropy
- 9.16 HELTMAN Medikal A.S.
- 9.16.1. Company Overview
- 9.16.2. Company Snapshot
- 9.16.3. Financial Overview
- 9.16.4 Product Listing
- 9.16.5. Entropy

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.17 Pneuma Respiratory
 - 9.17.1. Company Overview
 - 9.17.2. Company Snapshot
 - 9.17.3. Financial Overview
 - 9.17.4 Product Listing
 - 9.17.5. Entropy
- 9.18 Cipla Inc
 - 9.18.1. Company Overview
 - 9.18.2. Company Snapshot
 - 9.18.3. Financial Overview
 - 9.18.4 Product Listing
 - 9.18.5. Entropy
- 9.19 Microlife Corporation
 - 9.19.1. Company Overview
 - 9.19.2. Company Snapshot
 - 9.19.3. Financial Overview
 - 9.19.4 Product Listing
 - 9.19.5. Entropy
- 9.20 Honsun
 - 9.20.1. Company Overview
 - 9.20.2. Company Snapshot
 - 9.20.3. Financial Overview
 - 9.20.4 Product Listing
 - 9.20.5. Entropy
- 10. KOL Views
- 11. PROJECT APPROACH
- 12. About DelveInsight
- 13. Disclaimer & Contact Us

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Respiratory Inhalers - Market Insights, Competitive Landscape and Market Forecast-2027

Medical Market (7-10 Business Days) | 2022-07-01 | 100 pages | DelveInsight

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scottis-international.com

ORDER FORM:

Select license	License	Price
	Single User Price	\$2750.00
	Site License Price	\$5500.00
	Enterprise Price	\$8250.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scottis-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-16"/>
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scottis-international.com

www.scottis-international.com

